129 related articles for article (PubMed ID: 23603213)
1. External validation of the 2008 Framingham cardiovascular risk equation for CHD and stroke events in a European population of middle-aged men. The PRIME study.
Majed B; Tafflet M; Kee F; Haas B; Ferrieres J; Montaye M; Ruidavets JB; Arveiler D; Yarnell J; Amouyel P; Ducimetiere P; Empana JP;
Prev Med; 2013 Jul; 57(1):49-54. PubMed ID: 23603213
[TBL] [Abstract][Full Text] [Related]
2. Are the Framingham and PROCAM coronary heart disease risk functions applicable to different European populations? The PRIME Study.
Empana JP; Ducimetière P; Arveiler D; Ferrières J; Evans A; Ruidavets JB; Haas B; Yarnell J; Bingham A; Amouyel P; Dallongeville J;
Eur Heart J; 2003 Nov; 24(21):1903-11. PubMed ID: 14585248
[TBL] [Abstract][Full Text] [Related]
3. Performance of Framingham cardiovascular disease (CVD) predictions in the Rotterdam Study taking into account competing risks and disentangling CVD into coronary heart disease (CHD) and stroke.
van Kempen BJ; Ferket BS; Kavousi M; Leening MJ; Steyerberg EW; Ikram MA; Witteman JC; Hofman A; Franco OH; Hunink MG
Int J Cardiol; 2014 Feb; 171(3):413-8. PubMed ID: 24438922
[TBL] [Abstract][Full Text] [Related]
4. Predicting the impact of population level risk reduction in cardio-vascular disease and stroke on acute hospital admission rates over a 5 year period--a pilot study.
Whitfield MD; Gillett M; Holmes M; Ogden E
Public Health; 2006 Dec; 120(12):1140-8. PubMed ID: 17084425
[TBL] [Abstract][Full Text] [Related]
5. Education, socioeconomic and lifestyle factors, and risk of coronary heart disease: the PRIME Study.
Yarnell J; Yu S; McCrum E; Arveiler D; Hass B; Dallongeville J; Montaye M; Amouyel P; Ferrières J; Ruidavets JB; Evans A; Bingham A; Ducimetière P;
Int J Epidemiol; 2005 Apr; 34(2):268-75. PubMed ID: 15319403
[TBL] [Abstract][Full Text] [Related]
6. Prediction of coronary events in a low incidence population. Assessing accuracy of the CUORE Cohort Study prediction equation.
Ferrario M; Chiodini P; Chambless LE; Cesana G; Vanuzzo D; Panico S; Sega R; Pilotto L; Palmieri L; Giampaoli S;
Int J Epidemiol; 2005 Apr; 34(2):413-21. PubMed ID: 15659467
[TBL] [Abstract][Full Text] [Related]
7. Performance of Framingham cardiovascular risk scores by ethnic groups in New Zealand: PREDICT CVD-10.
Riddell T; Wells S; Jackson R; Lee AW; Crengle S; Bramley D; Ameratunga S; Pylypchuk R; Broad J; Marshall R; Kerr A
N Z Med J; 2010 Feb; 123(1309):50-61. PubMed ID: 20186242
[TBL] [Abstract][Full Text] [Related]
8. Comparison of three different methods of assessing cardiovascular disease risk in New Zealanders with Type 2 diabetes mellitus.
Metcalf PA; Wells S; Scragg RK; Jackson R
N Z Med J; 2008 Sep; 121(1281):49-57. PubMed ID: 18797484
[TBL] [Abstract][Full Text] [Related]
9. Validity of the Framingham point scores in the elderly: results from the Rotterdam study.
Koller MT; Steyerberg EW; Wolbers M; Stijnen T; Bucher HC; Hunink MG; Witteman JC
Am Heart J; 2007 Jul; 154(1):87-93. PubMed ID: 17584559
[TBL] [Abstract][Full Text] [Related]
10. Framingham Heart Study risk equation predicts first cardiovascular event rates in New Zealanders at the population level.
Milne R; Gamble G; Whitlock G; Jackson R
N Z Med J; 2003 Nov; 116(1185):U662. PubMed ID: 14615804
[TBL] [Abstract][Full Text] [Related]
11. Derivation and validation of a set of 10-year cardiovascular risk predictive functions in Spain: the FRESCO Study.
Marrugat J; Subirana I; Ramos R; Vila J; Marín-Ibañez A; Guembe MJ; Rigo F; Tormo Díaz MJ; Moreno-Iribas C; Cabré JJ; Segura A; Baena-Díez JM; de la Cámara AG; Lapetra J; Grau M; Quesada M; Medrano MJ; González Diego P; Frontera G; Gavrila D; Aicua EA; Basora J; García JM; García-Lareo M; Gutierrez JA; Mayoral E; Sala J; D'Agostino R; Elosua R;
Prev Med; 2014 Apr; 61():66-74. PubMed ID: 24412897
[TBL] [Abstract][Full Text] [Related]
12. Predictive accuracy of original and recalibrated Framingham risk score in the Swiss population.
Marques-Vidal P; Rodondi N; Bochud M; Chiolero A; Pécoud A; Hayoz D; Paccaud F; Mooser V; Firmann M; Waeber G; Vollenweider P
Int J Cardiol; 2009 Apr; 133(3):346-53. PubMed ID: 18485502
[TBL] [Abstract][Full Text] [Related]
13. Established cardiovascular disease and CVD risk factors in a primary care population of middle-aged Irish men and women.
Creagh D; Neilson S; Collins A; Colwell N; Hinchion R; Drew C; O'Halloran D; Perry IJ
Ir Med J; 2002; 95(10):298-301. PubMed ID: 12542011
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of the Framingham cardiovascular risk equation and the UKPDS risk engine for coronary heart disease in newly diagnosed Type 2 diabetes: results from a United Kingdom study.
Guzder RN; Gatling W; Mullee MA; Mehta RL; Byrne CD
Diabet Med; 2005 May; 22(5):554-62. PubMed ID: 15842509
[TBL] [Abstract][Full Text] [Related]
15. Ten-year risk prediction in French men using the Framingham coronary score: results from the national SU.VI.MAX cohort.
Vergnaud AC; Bertrais S; Galan P; Hercberg S; Czernichow S
Prev Med; 2008 Jul; 47(1):61-5. PubMed ID: 18456313
[TBL] [Abstract][Full Text] [Related]
16. Recalibration of a Framingham risk equation for a rural population in India.
Chow CK; Joshi R; Celermajer DS; Patel A; Neal BC
J Epidemiol Community Health; 2009 May; 63(5):379-85. PubMed ID: 19179368
[TBL] [Abstract][Full Text] [Related]
17. Prediction of first events of coronary heart disease and stroke with consideration of adiposity.
Wilson PW; Bozeman SR; Burton TM; Hoaglin DC; Ben-Joseph R; Pashos CL
Circulation; 2008 Jul; 118(2):124-30. PubMed ID: 18591432
[TBL] [Abstract][Full Text] [Related]
18. Recalibration and validation of the SCORE risk chart in the Australian population: the AusSCORE chart.
Chen L; Tonkin AM; Moon L; Mitchell P; Dobson A; Giles G; Hobbs M; Phillips PJ; Shaw JE; Simmons D; Simons LA; Fitzgerald AP; De Backer G; De Bacquer D
Eur J Cardiovasc Prev Rehabil; 2009 Oct; 16(5):562-70. PubMed ID: 19741542
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the Framingham and United Kingdom Prospective Diabetes Study cardiovascular risk equations in Australian patients with type 2 diabetes from the Fremantle Diabetes Study.
Davis WA; Colagiuri S; Davis TM
Med J Aust; 2009 Feb; 190(4):180-4. PubMed ID: 19220181
[TBL] [Abstract][Full Text] [Related]
20. Validity of an adaptation of the Framingham cardiovascular risk function: the VERIFICA Study.
Marrugat J; Subirana I; Comín E; Cabezas C; Vila J; Elosua R; Nam BH; Ramos R; Sala J; Solanas P; Cordón F; Gené-Badia J; D'Agostino RB;
J Epidemiol Community Health; 2007 Jan; 61(1):40-7. PubMed ID: 17183014
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
